Frankfurt
12.06.26 | 09:55
3,800 Euro
+3,26 % +0,120
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,820 | 3,880 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mi | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| Mi | B.Riley initiates Ascentage Pharma stock with buy, $45 target | 1 | Investing.com | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 | 2 | GlobeNewswire (USA) | ||
| 27.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| 27.05. | ASCENTAGE-B (06855): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER | - | HKEx | ||
| 22.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.05. | ASCENTAGE-B Has Six Studies Selected for Abstracts at American Society of Clinical Oncology Annual Meeting | 1 | AASTOCKS | ||
| 22.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | 178 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company... ► Artikel lesen | |
| 22.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST CLINICAL DATA FROM MULTIPLE TRIALS AT ASCO 2026 | 1 | HKEx | ||
| 21.05. | ASCENTAGE-B (06855): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 20.05. | ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026 | 1 | HKEx | ||
| 18.05. | TGI Solar Power Group, Inc.: TGI Solar Power Group CEO Samuel Epstein Elected Secretary/Editor of AAPG House of Delegates; Company Accelerates AXINOD Sovereign AI Strategy | 380 | ACCESS Newswire | Company Concurrently Signals Expansion into High-Growth Sovereign AI Market with AXINOD Modular Infrastructure Strategy MIAMI, FL / ACCESS Newswire / May 18, 2026 / TGI SOLAR POWER GROUP INC. (OTC Markets:TSPG)... ► Artikel lesen | |
| 14.05. | Ascentage Pharma: Interview With Co-Founder & CEO Dr. Dajun Yang About The Global Hematology-Oncology Company | 4 | pulse2.com | ||
| 13.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress | 1 | GlobeNewswire (USA) | ||
| 12.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.04. | ASCENTAGE-B (06855): SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026 | - | HKEx |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,95 | +1,43 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| OCUGEN | 1,050 | 0,00 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 25,150 | +1,21 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO, June 11, 2026 /PRNewswire/... ► Artikel lesen | |
| INFLARX | 1,388 | 0,00 % | ANALYSE: InflaRx NV: Könnte die Aktie jetzt komplett einbrechen? - Was Sie über das Wochenende vorbereiten sollten | ||
| EDITAS MEDICINE | 2,180 | +0,93 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,080 | -1,06 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| CARDIOL THERAPEUTICS | 0,907 | +0,44 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 54,10 | -0,18 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 64,04 | -0,59 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 7,960 | -4,07 % | Prediction: I think Telix shares could double in value in 2026. Here's why | ||
| ONCO-INNOVATIONS | 0,471 | -2,89 % | Onco-Innovations meldet Start des Programms zur API-Prozessentwicklung und Zwischenprodukt-Skalierung für seine proprietäre PNKP-Inhibitor-Technologie | Vancouver, Kanada - 9. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich, den Beginn der Prozessentwicklung... ► Artikel lesen | |
| TWIST BIOSCIENCE | 65,86 | 0,00 % | Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains? | ||
| REPLIGEN | 114,75 | +1,64 % | Repligen Corporation: Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance | First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26... ► Artikel lesen | |
| UNIQURE | 24,000 | +0,84 % | uniQure Inc.: uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates | ~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~
~ Progressing AMT-130 toward expected UK regulatory submission; MAA on... ► Artikel lesen | |
| REVOLUTION MEDICINES | 133,00 | +0,08 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen |
ASCENTAGE PHARMA GROUP INTERNATIONAL gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,26 % bei einem Aktienkurs von 3,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.